Skip to main content

Table 3 Mutated genes across age of onset groups

From: Mutational landscape differences between young-onset and older-onset breast cancer patients

GeneYoungOlderOldestp-value (young vs. older)p-value (young vs. oldest)
TP5331(34%)320(33.6%)133(28.6%)0.910.32
PIK3CA22(24%)340(35.7%)174(37.4%)0.03*0.02*
GATA320(22%)123(12.9%)50(10.8%)0.02*0.01*
TAF19(10%)73(7.7%)40(8.6%)0.420.69
PTEN7(8%)58(6.1%)32(6.9%)0.500.82
NF16(7%)97(10.2%)57(12.3%)0.360.15
ATM6(7%)70(7.4%)35(7.5%)1.001.00
MORC46(7%)59(6.2%)29(6.2%)0.820.82
ARID1A6(7%)58(6.1%)27(5.8%)0.820.81
NIPBL5(5%)66(6.9%)38(8.2%)0.830.52
CTNNB15(5%)14(1.5%)10(2.2%)0.02*0.08
CDH14(4%)170(17.9%)96(20.6%)0.0003*0.0001*
PIK3R14(4%)58(6.1%)35(7.5%)0.650.37
MAP2K44(4%)53(5.6%)26(5.6%)0.810.80
RB14(4%)49(5.1%)23(4.9%)1.001.00
PPP2R1A4(4%)34(3.6%)23(4.9%)0.571.00
AKT14(4%)32(3.4%)14(3%)0.550.51
MAP3K13(3%)108(11.3%)66(14.2%)0.01*0.003*
BRCA13(3%)47(4.9%)26(5.6%)0.610.60
CHD43(3%)47(4.9%)28(6%)0.610.45
EP3003(3%)40(4.2%)20(4.3%)1.001.00
HCFC23(3%)19(2%)10(2.2%)0.430.46
RPL223(3%)13(1.4%)9(1.9%)0.160.43
RUNX12(2%)62(6.5%)33(7.1%)0.110.10
FBXW72(2%)33(3.5%)16(3.4%)0.760.75
ZC3H132(2%)32(3.4%)17(3.7%)0.760.75
RASA12(2%)31(3.3%)16(3.4%)1.000.75
CTCF2(2%)29(3%)14(3%)1.001.00
ACVR2A2(2%)28(2.9%)17(3.7%)1.000.75
ARID5B2(2%)26(2.7%)18(3.9%)1.000.76
SPOP2(2%)20(2.1%)7(1.5%)1.000.65
RNF432(2%)14(1.5%)11(2.4%)0.641.00
TBX31(1%)51(5.4%)27(5.8%)0.080.07
CCAR11(1%)30(3.2%)16(3.4%)0.510.33
CASP81(1%)26(2.7%)14(3%)0.500.48
LARP71(1%)21(2.2%)13(2.8%)0.710.49
CDKN1B1(1%)13(1.4%)6(1.3%)1.001.00
RPL51(1%)13(1.4%)11(2.4%)1.000.70
KRAS1(1%)12(1.3%)8(1.7%)1.001.00
CD3G1(1%)10(1.1%)5(1.1%)1.001.00
LATS11(1%)10(1.1%)6(1.3%)1.001.00
CCND11(1%)3(0.3%)1(0.2%)0.310.30
PIK3R30(0%)18(1.9%)12(2.6%)0.390.23
PRRG10(0%)13(1.4%)10(2.2%)0.620.38
B2M0(0%)8(0.8%)4(0.9%)1.001.00
AP1S10(0%)7(0.7%)5(1.1%)1.001.00
  1. Frequency and proportion of patients in each age of onset group with mutations in 46 genes of interest. Entries are number of samples with at least one mutation in a given gene (% of samples in age of onset group). The genes of interest were selected based on Berger et al.’s study of gynecologic and breast cancers using TCGA data [30]. The p-values were calculated using a chi squared test for difference in proportions (* indicates statistical significance at the 0.05 level). Age of onset groups were defined as “Young”: breast tumours diagnosed ≤40 years of age (n = 91), “Older”: breast tumours diagnosed > 40 years of age (n = 952), and “Oldest”: breast tumours diagnosed > 60 years of age (n = 465). HER2+: human epidermal growth factor receptor 2 over-expressing